Itcure, a prominent gene editing specialist headquartered in Suzhou, has announced separate strategic collaborations with two domestic biotechnology companies: Lakeshore Biotechnology, a cell and gene therapy (CGT) focused biotech, and Porton Pharma Solutions, Ltd., a CGT contract research organization (CRO) and contract development and manufacturing organization (CDMO).
In July, Itcure granted Lakeshore a global commercialization license to utilize its EnCas12Ultra edited protein, enabling the development and manufacturing of induced pluripotent stem cell (iPSC) therapies.
Subsequently, in September, Itcure and Porton entered into an agreement to jointly explore advancements in gene editing systems, gene editing fusion proteins such as the CAS12 protein, and non-integrated viral particle (VLP) delivery systems, with the aim of enhancing the development and commercialization of gene editing therapies. The financial specifics of these agreements were not disclosed.
Porton Pharma Solutions brings to the table a comprehensive end-to-end CGT CDMO platform, encompassing services for plasmids, viral vectors, mRNA, and a range of autologous and allogeneic immune cells. Itcure, on the other hand, prides itself on possessing a world-leading and comprehensive gene editing and epigenetic toolkit, along with a structurally unique VLP delivery system. This system facilitates efficient in vitro and in vivo target gene editing, long-acting target gene inhibition, and the effective delivery of proteins, mRNA, or RNP protein complexes. – Flcube.com
